Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

SN, Gettinger; L, Horn; L, Gandhi; DR, Spigel; SJ, Antonia; NA, Rizvi; JD, Powderly; RS, Heist; RD, Carvajal; DM, Jackman; LV, Sequist; DC, Smith; P, Leming; DP, Carbone; MC, Pinder-Schenck; SL, Topalian; FS, Hodi; JA, Sosman; M, Sznol; DF, McDermott; DM, Pardoll; V, Sankar; CM, Ahlers; M, Salvati; JM, Wigginton; MD, Hellmann; GD, Kollia; AK, Gupta; JR, Brahmer

doi:10.1200/jco.2014.58.3708

Public

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Shared by NobleBlocks on Apr 20, 2015 • 12:00 AM UTC

Authors:

Gettinger SN

Horn L

Gandhi L

Abstract

<h4>Purpose</h4>Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!